Logo for Mineralys Therapeutics Inc

Mineralys Therapeutics Investor Relations Material

Latest events

Logo for Mineralys Therapeutics Inc

Study Result

Mineralys Therapeutics
Logo for Mineralys Therapeutics

Study Result

10 Mar, 2025
Logo for Mineralys Therapeutics

Q4 2024

12 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies

Latest reports from Mineralys Therapeutics Inc

Access all reports
Mineralys Therapeutics Inc. (MLYS) is a clinical-stage biopharmaceutical company developing treatments for diseases associated with abnormally elevated aldosterone levels. The company's flagship product candidate, lorundrostat, is a highly selective aldosterone synthase inhibitor, currently under investigation for its potential in treating hypertension. The company is headquartered in Radnor, Pennsylvania, and its shares are listed on the Nasdaq.